Internal Medicine, Rheumatology · Honolulu, HI
NPI
1689663890
Since 2005
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2828 Paa St
Honolulu, HI, 96819
Phone (808) 432-5777
Groups this clinician bills Medicare through
Medicare paid, 2024
$2,132
52 services
Medicare patients, 2024
22
Average age 74
Drug cost, 2024
$2.1M
2,464 prescriptions
Company payments, 2023
$25.37
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Finger was code 99214 (office e&m - established), 24 times for 16 patients. In total David R Finger billed 52 services in 11 codes, and Medicare paid $2,132.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 24 | 16 | $53.22 | $1,277 |
By year: 2022 $2,382 for 81 services; 2023 $2,216 for 90 services; 2024 $2,132 for 52 services.
Medicare prescription drug claims, 2024
In 2024, the drug David R Finger prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 388 prescriptions and refills. In total David R Finger wrote 2,464 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 388 | 1,129 | 127 | $7,347 |
| Prednisone Generic | 307 | 502 | 109 | $2,578 |
| Hydroxychloroquine Sulfate Generic | 241 | 662 | 67 | $6,792 |
| Amjevita(Cf) Autoinjector Adalimumab-Atto | 187 | 199 | 24 | $183K |
| Leflunomide Generic | 162 | 436 | 54 | $4,259 |
| Xeljanz Tofacitinib Citrate | 135 | 154 | 18 | $396K |
| Duloxetine Hcl Generic | 115 | 286 | 34 | $2,076 |
| Enbrel Sureclick Etanercept | 73 | 77 | Under 11 | $380K |
| Alendronate Sodium Generic | 62 | 170 | 20 | $604 |
| Meloxicam Generic | 59 | 89 | 13 | $353 |
| Cevimeline Hcl Generic | 44 | 82 | Under 11 | $7,852 |
| Xeljanz Xr Tofacitinib Citrate | 41 | 41 | Under 11 | $204K |
| Gabapentin Generic | 41 | 89 | 12 | $785 |
| Sulfasalazine Generic | 29 | 83 | Under 11 | $2,068 |
| Actemra Tocilizumab | 28 | 28 | Under 11 | $91K |
Brand drugs: 721 claims; generic drugs: 1,743 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid David R Finger $25.37 ($25.37 in general payments such as food, travel and fees) from 1 company. The largest payer was Nevro Corp. with $25.37.
| Company | Payments | Amount |
|---|---|---|
| Nevro Corp. | 1 | $25.37 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.